Trial Profile
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 01 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 07 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.